US2016256563A1PendingUtilityA1
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
Est. expiryFeb 8, 2030(~3.5 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 1/16A61K 47/6811A61K 47/6861A61K 47/6849A61P 13/12A61K 39/39558A61K 2039/505C07K 2317/56A61K 47/42C07K 2317/92C07K 16/28A61K 47/50C07K 16/3038C07K 2317/21A61K 39/395A61K 47/48607A61K 47/48561A61K 47/48415
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . An antibody drug conjugate, comprising an antibody or antigen binding fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the amino acid sequence of the V H region of SEQ ID NO:7, from 20 to 142, and the V L region of SEQ ID NO:8, from 20 to 127 and wherein said antibody is conjugated to monomethyl auristatin F (MMAF).Join the waitlist — get patent alerts
Track US2016256563A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.